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Abstract
Background Controversy exists on the impact of bi-
laterality of breast cancer on survival. We used popu-
lation-based data to compare survival of women with
unilateral versus bilateral breast cancer.
Patients and methods At the Geneva cancer registry,
we identified all 7,912 women diagnosed with invasive
breast cancer between 1970 and 2002. Breast cancers
were categorized as unilateral, synchronous bilateral
(contralateral tumour diagnosed within six months
after the first tumour) and metachronous bilateral
(contralateral tumour diagnosed over six months after
the first tumour). With multivariate modelling we
compared characteristics and survival between women
with unilateral and bilateral disease.
Results Patients with synchronous bilateral tumours
(n = 155, 2.0%) had more often lobular histology and
less frequently stage I disease than women with uni-
lateral disease. Women with metachronous breast
cancer (n = 219, 2.8%) received less often chemo-
therapy or hormone therapy for their first tumours.
Ten-year disease-specific survival was similar (66%)
after unilateral and metachronous bilateral breast
cancer, but worse after synchronous bilateral cancer
(51%). After adjustment, breast cancer mortality risks
were not significantly increased for women with either
synchronous or metachronous bilateral disease (Haz-
ard ratios 1.1 (0.8–1.5) and 0.8 (0.5–1.4), respectively).
Conclusion This large population-based study indi-
cates that bilaterality of breast cancer is not associated
with impaired survival.
Keywords Bilateral  Breast cancer  Population-
based  Survival
Introduction
Bilateral breast cancer is relatively rare, but has an
important emotional impact on the patient. Having two
breast cancers instead of one requires more extensive
locoregional treatment and is thought to carry a worse
outcome. The causes and the prognostic consequences
of bilateral breast cancer are far from being estab-
lished.
Epidemiological studies on the risk factors for
bilateral breast cancer are scarce [1, 2]. Women with
bilateral breast cancer have more frequently a positive
family history of breast cancer compared to women
with unilateral disease [3–7]. Women who develop
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breast cancer at young age also have an increased
risk to develop a contralateral tumour [8]. This is
explained by their longer overall life expectancy and
by the fact that they more often belong to high-risk
families [9, 10].
Female breast cancer patients who carry germ-line
mutations in the BRCA1 or BRCA2 genes (the main
genes involved in genetic predisposition to breast
cancer) have an annual risk of 2–6% of developing
contralateral breast cancer [11]. However, as the
prevalence of BRCA1 and BRCA2 mutations is very
low, most bilateral breast cancer patients do not carry
BRCA1 and BRCA2 mutations [12].
It is unclear whether contralateral breast cancer
occurrence, either synchronous or metachronous, has
an impact on survival. Some studies found worse
survival for patients with bilateral breast cancer
[13–15], others showed similar survival rates for
patients with unilateral and bilateral breast cancer
[3–5, 13–21]. Unfortunately, many of these studies did
not account for important prognostic factors such as
systemic therapy.
The aim of this study is to evaluate the impact of
contralateral breast cancer occurrence on survival.
Patients and methods
The Geneva cancer registry records all incident cancer
cases occurring in the population of the canton
(approximately 420,000 inhabitants) since 1970. It
collects information from various sources and only less
than 2% of cases are recorded from death certificates
only [22]. All hospitals, pathology laboratories and
private practitioners in the canton are requested to
report every cancer case. Trained tumour registrars
systematically abstract data from medical files. Physi-
cians regularly receive questionnaires to complete
missing clinical and therapeutic data. Recorded data
include socio-demographic information, method of
discovery, tumour characteristics (coded according
to the International Classification of Diseases for
Oncology, ICD-O) [23], stage of disease at diagnosis,
hormone receptor status and treatment during the
first 6 months after diagnosis. The registry regularly
assesses survival, taking as reference date the date of
confirmation of diagnosis or the date of hospitalization
(if it preceded the diagnosis and was related to the
disease). In addition to passive follow-up (standard
examination of death certificates and hospital records),
active follow-up is performed yearly using the files
of the Cantonal Population Office. Cause of death is
taken from clinical files.
We included all patients diagnosed with primary
invasive breast cancer between 1970 and 2002, living in
the canton of Geneva. We excluded women diagnosed
at death/autopsy (n = 95) and women with contralat-
eral in situ breast cancer (n = 88).
Bilateral breast cancer was classified as synchronous
in patients with a second invasive breast cancer diag-
nosed within six months after the first breast cancer
and as metachronous if the second breast cancer oc-
curred more than six months after the first.
Variables of interest were age, social class (high,
middle, low, unknown), sector of care (private vs.
public) and period of diagnosis. Familial risk was
available for breast cancer patients diagnosed after
1990 and categorized as low (no first-or second-degree
relative with breast or ovarian cancer), high (either ‡1
first-degree relative with breast or ovarian cancer
£50 years, ‡2 first-degree relatives with breast/ovarian
cancer at any age, or ‡3 patient cases of breast/ovarian
cancer among first-or second-degree relatives) or
moderate (all other family histories of breast and/or
ovarian cancer).
For staging, we used the pathologic pTNM (Tumour
Node Metastasis) classification system or, when not
available, the clinical cTNM classification [24]. Tumour
differentiation (grade) was classified as well (grade 1),
moderately (grade 2) or poorly differentiated (grade
3), or unknown. Information on oestrogen receptor
status was available since 1995 and considered positive
when ‡10% of the tumour cells expressed oestrogen
receptors. Tumour histology was classified as ductal
(ICD-O code 8500), lobular (ICD-O code 8520 or
8522) and other.
Locoregional therapy was categorized as breast-
conserving surgery followed by radiotherapy, mastec-
tomy with or without radiotherapy, and other (i.e. tu-
morectomy without radiotherapy and no surgery). Use
of chemotherapy and hormone therapy was catego-
rized as yes versus no/unknown.
For the comparison of tumour characteristics be-
tween women with synchronous bilateral breast cancer
and those with unilateral disease, we considered the
tumour with the most advanced stage and the highest
grade. The oestrogen receptor status was considered
negative if either one or both tumours were oestrogen
receptor negative. Patients with at least one lobular
tumour were categorized as having lobular histology.
To compare tumour and treatment characteristics of
patients with metachronous bilateral breast cancer
with those with unilateral disease, we used the char-
acteristics of the first metachronous tumour.
With unconditional logistic regression analysis we
identified all variables significantly associated with
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synchronous or metachronous breast cancer. To
determine which variables were both independently
and significantly associated with synchronous or
metachronous bilateral disease, we used multivariate
logistic regression analysis, adjusting for all variables
that were significant in univariate analysis.
Disease-specific survival rates were calculated with
Kaplan–Meier analysis. With Cox proportional hazards
analysis we identified the variables significantly linked
to prognosis. Finally, we calculated breast cancer
mortality risks (hazard ratio’s [HR]) for patients with
synchronous and metachronous bilateral breast cancer
compared with patients with unilateral disease cancer
and adjusted these risks for other prognostic factors.
For women with metachronous breast cancer we cal-
culated survival from the date of diagnosis of the sec-
ond tumour.
Results
This study included 7,912 patients of whom 155 (2.0%)
had synchronous bilateral breast cancer and 219
(2.8%) developed metachronous bilateral breast can-
cer after a median follow-up of 6.7 years. In univariate
analysis, patients with synchronous bilateral breast
cancer were significantly older, belonged more often to
lower social class and were more often treated in the
public sector (Table 1). These patients reported more
frequently a strong family history of breast and/or
ovarian cancer, but this difference was not statistically
significant. They presented with later stage at diagnosis
and had more often lobular histology. There were no
significant differences in grade and oestrogen receptor
status.
After adjustment for age, social class, sector of care,
stage, and histologic subtype, both higher stage and
histology (lobular subtype) remained independently
and significantly associated with synchronous breast
cancer. Compared with patients with stage I disease,
patients with stage II disease had a twofold increased
risk of synchronous bilateral breast cancer (Odds Ratio
[OR], 2.2; 95% CI, 1.4–3.5), and those with stage III
disease had a threefold increased risk (OR, 2.9; 95%
CI, 1.7–5.1). Lobular histology increased the risk for
synchronous bilateral disease more than threefold
(OR, 3.5; 95% CI, 2.3–5.4). Patients with synchronous
bilateral breast cancer were significantly more often
treated with mastectomy (71% vs. 49% of unilateral
patients, P < 0.001) and received significantly more
often chemotherapy (36% vs. 28% of unilateral
patients, P = 0.035) and hormone therapy (47% vs.
36% of unilateral patients, P = 0.001).
Patients who developed metachronous breast cancer
were significantly younger at the time of their first
breast cancer and were more often diagnosed during
the early years of the study (Table 2). We observed no
differences in social class or sector of care. Patients
with metachronous bilateral breast cancer had more
often a highly increased familial risk, but this differ-
ence was not significant. Also, they had less often dis-
tant metastases at the time of diagnosis of their first
tumour. The proportions of stage I, II, and III disease
were not significantly different from women with uni-
lateral disease. There were no significant differences in
tumour grade. Women with metachronous bilateral
disease had significantly more often oestrogen receptor
negative disease at the time of diagnosis of their first
tumour and less often histology other than ductal or
lobular. Women who developed metachronous bilat-
eral breast cancer underwent more often mastectomy
for their first tumour, and had less often chemotherapy
or hormone therapy. After adjustment for all variables
univariately linked to metachronous bilateral cancer,
women with oestrogen receptor positive tumours had a
lower risk of developing contralateral breast cancer
than women with oestrogen receptor negative disease
(OR, 0.2; 95% CI, 0.1–0.7). Breast cancer treatment
regimens not including systemic chemotherapy or
hormone therapy were also significantly and indepen-
dently associated with contralateral breast cancer
occurrence (OR, 1.8; 95% CI, 1.2–2.6, and OR, 2.0;
95% CI, 1.2–3.4, respectively). Patients with histology
other than ductal or lobular for their first tumours re-
mained at significantly decreased risk of developing
contralateral disease (OR, 0.3; 95% CI, 0.2–0.5).
Five-year disease-specific survival rates for women
with unilateral breast cancer, synchronous bilateral
breast cancer and (second) metachronous bilateral
breast cancer were 78% (95% CI, 77–79%), 77% (95%
CI, 69–85%) and 80% (95% CI, 74–86%), respectively
(Fig. 1). Ten-year disease-specific survival rates were
66% (95% CI, 65–67%), 51% (95% CI, 39–63%) and
66% (95% CI, 58–74%), respectively.
In univariate analysis, recognized prognostic vari-
ables, such as lower social class, advanced stage, poor
differentiation, negative oestrogen receptor status,
extensive locoregional therapy, use of chemotherapy
and hormone therapy, but also breast cancer diagnosed
in the earlier years of the study, and non-ductal or non-
lobular histology, significantly increased the risk of
death from breast cancer (data not shown).
Before adjustment, patients with synchronous
bilateral breast cancer had a 40% excess risk of death
as a result of their disease (Hazard ratio [HR], 1.4;
95% CI, 1.1–1.8) (Table 3). After adjustment for the
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Table 1 Comparison of characteristics of patients with synchronous bilateral breast cancer and unilateral breast cancer
Synchronous bilateral breast cancer Unilateral breast
cancer
Unadjusted odds
ratio
Multiadjusted odds
ratioa
Age
> 75 37(24%) 1,528 (20%) 1b 1b
51–75 90 (58%) 4,132 (55%) 0.9(0.3–1.3) 0.9 (0.6–1.4)
41–50 24 (16%) 1,402 (19%) 0.7(0.4–1.2) 0.7 (0.4–1.3)
< 41 4 (3%) 476 (6%) 0.3 (0.1–1.0) 0.4 (0.1–1.1)
Civil status
Single 24 (16%) 1,038 (14%) 1b 1b
Married 63 (41%) 3,838 (51%) 0.7 (0.4–1.1) 0.7 (0.4–1.1)
Widowed 45 (29%) 1,645 (22%) 1.2 (0.7–2.0) 1.1 (0.6–1.9)
Separated 23 (15%) 1,017 (14%) 1.0 (0.5–1.7) 1.0 (0.5–1.7)
Social class
High 16 (10%) 1,232 (16%) 1b 1b
Middle 75 (48%) 3,701 (49%) 1.6 (0.9–2.7) 1.5 (0.9–2.6)
Low 49 (32%) 1,926 (26%) 2.0 (1.1–3.5) 1.7 (0.9–3.1)
Unknown 15 (10%) 679 (9%) – –
Sector of care
Private 61 (39%) 3,695 (49%) 1b 1b
Public 94 (61%) 3,843 (51%) 1.5 (1.1–2.1) 1.3 (0.9–1.8)
Period of diagnosis
1970–1979 27(17%) 1,751 (23%) 1b 1b
1980–1989 49 (32%) 2,028 (27%) 1.6 (1.0–2.5) 1.2 (0.7–2.0)
1990–2002 79 (51%) 3,759 (50%) 1.4 (0.9–2.1) 1.0 (0.6–1.5)
Familial risk
Low (not increased) 52 (34%) 2,297 (31%) 1b 1b
Moderate 11 (7%) 643 (9%) 0.8 (0.4–1.5) 0.7 (0.4–1.4)
High 6 (4%) 170 (2%) 1.6 (0.7–3.7) 1.5 (0.6–3.6)
Not availablec 86 (56%) 4,428 (59%) – –
Staged Most advanced tumour Less advanced tumour
I 26 (17%) 85 (54%) 2,260 (30%) 1b 1b
II 82 (53%) 53 (34%) 3,171 (42%) 2.2 (1.4–3.5) 2.2 (1.4–3.5)
III 30 (19%) 5 (3%) 857 (11%) 3.0 (1.8–5.2) 2.9 (1.7–5.1)
IV 9 (6%) 4 (3%) 451 (6%) 1.7 (0.8–3.7) 1.7 (0.8–3.8)
Unknown 8 (5%) 8 (5%) 799 (11%) – –
Differentiatione Tumour with highest
grade
Tumour with lowest
grade
Well 27 (17%) 43 (28%) 1,118 (15%) 1b 1b
Moderate 39 (25%) 41 (27%) 1,798 (24%) 0.9 (0.5–1.5) 0.7 (0.5–1.2)
Poor 26 (17%) 8 (5%) 998 (13%) 1.1 (0.6–1.9) 1.0 (0.6–1.8)
Unknown 63 (41%) 63 (41%) 3,624 (48%) – –
Oestrogen receptor status
Positive 36 (23%) 1,871 (25%) 1b 1b
Negative 9 (6%) 400 (5%) 1.2 (0.6–2.4) 1.4 (0.7–3.0)
Unknown 110 (71%) 5,267 (70%) – –
Histology
Ductal (both) 98 (63%) 4,969 (66%) 1b 1b
Lobular (at least one) 32 (21%) 494 (7%) 3.3 (2.2–4.9) 3.5 (2.3–5.4)
Other 25 (16%) 2,075 (28%) 0.6 (0.4–1.0) 0.5 (0.3–0.8)
Locoregional therapy
BCS + radiotherapy 23 (15%) 22 (14%) 2,206 (29%) P < 0.0001
Mastectomy +/–
radiotherapy
109 (71%) 110 (71%) 3,726 (49%)
Other 23 (15%) 23 (15%) 1,606 (21%)
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Table 1 continued
Synchronous bilateral breast cancer Unilateral breast
cancer
Unadjusted odds
ratio
Multiadjusted odds
ratioa
Chemotherapy
Yes 56 (36%) 2,140 (28%) P = 0.035
No/unknown 99 (64%) 5,398 (72%)
Tamoxifen
Yes 73 (47%) 2,719 (36%) P = 0.005
No/unknown 82 (53%) 4,819 (63%)
a Adjusted for age, social class, sector of care, stage, and morphology
b Reference category
c Family history was only recorded for women diagnosed after 1990
d For comparison of stage, the stage of the most advanced bilateral tumour was taken into account
e Differentiation was only recorded for women diagnosed after 1985
Table 2 Comparison of characteristics of patients with synchronous bilateral breast cancer and unilateral breast cancer
Metachronous bilateral
breast cancer
Unilateral breast
cancer
Unadjusted odds
ratio
Multiadjusted
odds ratioa
Age category First tumour Second tumour
76+ 14 (6%) 42 (19%) 1,528 (20%) 1b 1b
51–75 102 (47%) 126 (58%) 4,132 (55%) 2.6 (1.5–4.7) 2.7 (1.5–4.8)
41–50 77 (35%) 43 (20%) 1,402 (19%) 6.0 (3.4–10.6) 5.7 (3.1–10.5)
<41 26 (12%) 8 (4%) 476 (6%) 6.0 (3.0–11.5) 5.4 (2.7–10.7)
Civil status
Single 31 (14%) 1,038 (14%) 1b 1b
Married 129 (59%) 3,838 (51%) 1.1 (0.8–1.7) 1.0 (0.6–1.5)
Widowed 32 (15%) 1,645 (22%) 0.7 (0.4–1.1) 1.1 (0.6–1.8)
Separated 27 (12%) 1,017 (14%) 0.9 (0.5–1.5) 0.9 (0.5–1.6)
Social class
High 32 (15%) 1,232 (16%) 1b 1b
Middle 121 (55%) 3,701 (49%) 1.3 (0.8–1.9) 1.4 (0.9–2.1)
Low 47 (22%) 1,926 (26%) 0.9 (0.6–1.5) 1.0 (0.6–1.6)
Unknown 19 (9%) 679 (9%) – –
Sector of care First tumour Second tumour
Private 114 (52%) 101 (46%) 3,695 (49%) 1b 1b
Public 105 (48%) 118 (54%) 3,843 (51%) 0.9 (0.7–1.2) 1.0 (0.7–1.3)
Period First tumour Second tumour
1970–1979 92 (42%) 31 (14%) 1,751 (23%) 1b,c 1b,c
1980–1989 86 (39%) 70 (32%) 2,028 (27%) 0.8 (0.6–1.1) 0.9 (0.6–1.2)
1990–2002 41 (19%) 118 (54%) 3,759 (50%) 0.2 (0.1–0.3) 0.4 (0.2–0.6)
Familial riskd
Not increased 85 (39%) 2,297 (31%) 1b
Moderately increased 20 (9%) 643 (9%) 0.8 (0.5–1.4) 1.0 (0.4–2.1)
Highly increased 8 (4%) 170 (2%) 1.3 (0.6–2.7) 1.8 (0.6–5.3)
Unknown 106 (48%) 4,428 (59%) – –
Stage First tumour Second tumour
I 72 (33%) 101 (46%) 2,260 (30%) 1b 1b
II 102 (47%) 72 (33%) 3,171 (42%) 1.0 (0.7–1.4) 1.0 (0.7–1.4)
III 18 (8.2%) 16 (7%) 857 (11%) 0.7 (0.4–1.1) 0.8 (0.4–1.3)
IV 3 (1%) 10 (5%) 451 (6%) 0.2 (0.1–0.7) 0.4 (0.1–1.3)
Unknown 24 (11%) 20 (9%) 799 (11%) – –
Differentiatione First tumour Second tumour
Well 17 (13%) 35 (16%) 1,118 (15%) 1b 1b
Moderate 26 (19%) 65 (30%) 1,798 (24%) 1.0 (0.5–1.8) 0.9 (0.5–1.8)
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other prognostic variables, the risk of death from
breast cancer was no longer significantly increased for
synchronous bilateral breast cancer patients (multiad-
justed HR, 1.1; 95% CI, 0.9–1.5). Before adjustment,
women with metachronous bilateral disease had a
similar risk of death from breast cancer after their
Table 2 continued
Metachronous bilateral
breast cancer
Unilateral breast
cancer
Unadjusted odds
ratio
Multiadjusted
odds ratioa
Poor 22 (16%) 22 (10%) 998 (13%) 1.5 (0.8–2.7) 1.5 (0.8–2.9)
Unknown 71 (52%) 97 (44%) 3,624 (48%) – –
Oestrogen receptorf First tumour Second tumour
Negative 8 (4%) 13 (6%) 400 (5%) 1b 1b
Positive 8 (4%) 62 (28%) 1,871 (25%) 0.2 (0.1–0.6) 0.2 (0.1–0.7)
Unknown 203 (93%) 144 (66%) 5,267 (70%) – –
Histology First tumour Second tumour
Ductal 168 (77%) 164 (75%) 4,969 (66%) 1b 1b
Lobular 9 (4%) 25 (11%) 494 (7%) 0.5 (0.3–1.1) 0.8 (0.4–1.6)
Other 42 (19%) 30 (14%) 2,075 (28%) 0.6 (0.4–0.8) 0.3 (0.2–0.5)
Locoregional therapy First tumour Second tumour
BCS + radiotherapy 33 (15%) 39 (18%) 2,206 (29%) 1b 1b
Mastectomy +/– radiotherapy 166 (76%) 134 (61%) 3,726 (49%) 3.0 (2.0–4.3) 1.5 (0.9–2.3)
Other 20 (9%) 36 (22%) 1,606 (21%) 0.8 (0.5–1.5) 1.1 (0.6–2.1)
Chemotherapy
With 39 (18%) 48 (22%) 2,140 (28%) 1b 1b
Without/unknown 180 (82%) 171 (78%) 5,398 (72%) 1.8 (1.3–2.6) 1.8 (1.2–2.6)
Tamoxifen
With 22 (10%) 88 (40%) 2,719 (36%) 1b 1b
Without/unknown 197 (90%) 131 (60%) 4,819 (64%) 5.1(3.2–7.9) 2.0 (1.2–3.4)
a Adjusted for age, period of diagnosis, stage, locoregional therapy, chemotherapy, hormone therapy. Due to the high proportion of
patients with unknown oestrogen receptor status, this variable was not incorporated in multivariate analysis
b Reference category
c In this comparison, period of diagnosis of the first bilateral tumour was taken into account
d Family history was only recorded for women diagnosed after 1990
e Tumour differentiation was only recorded for women diagnosed after 1985
f Oestrogen receptor status was only recorded for women diagnosed after 1995
0.4
0.5
0.6
0.7
0.8
0.9
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0 1 2 3 4 5 6 7 8 9 10
years
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unilateral breast cancer
synchronous bilateral breast cancer
second metachronous bilateral breast
cancer
Numbers at risk
Unilateral 7,538 6,645 5,802 5,032 4,380 3,793 3,310 2,887 2,529 2,214
Synchronous 155 138 124 99 85 72 61 54 42 32
Metachronous 219 190 159 147 120 104 92 79 70 60
Fig. 1 Disease-specific survival after unilateral, synchronous bilateral and second metachronous bilateral breast cancer
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second tumour as breast cancer patients who never had
breast cancer before (HR, 1.0; 95% CI, 0.8–1.3) which
remained similar after adjustment for all prognostic
variables (multiadjusted HR, 0.8; 95% CI, 0.5–1.4).
(Table 3).
Discussion
Patients with synchronous or metachronous bilateral
breast cancer have the same risk of death from breast
cancer as patients with unilateral disease. This means
that having two breast cancers instead of one per se is
not predictive of a worse prognosis. In addition, pa-
tients with synchronous and metachronous bilateral
breast cancer do not share similar characteristics. The
risk of synchronous bilateral cancer is three times
higher in patients with stage III disease and in patients
with lobular histology, while the risk of metachronous
cancer is not influenced by these factors. Metachronous
breast cancer, on the other hand, was more common in
patients with oestrogen receptor negative disease and
in women who did not receive adjuvant systemic
treatment. The risk of metachronous cancer was higher
in young women, while older women had an increased
risk of synchronous bilateral breast cancer.
Previous investigators have reported higher rates of
lobular histology among women with synchronous
breast cancer [18, 25, 26]. Among the 526 patients at
the Geneva cancer registry diagnosed with lobular
histology, 32 (6.1%) had synchronous bilateral disease
versus 98 (1.9%) of the 5,067 patients with ductal
cancer. This higher risk of synchronous contralateral
disease opens the question whether patients diagnosed
with lobular breast cancer should undergo contralat-
eral breast MRI to rule out simultaneous malignancy.
Interestingly, lobular histology was not associated with
an increased risk of developing contralateral breast
cancer later in life.
As already previously demonstrated, we found that
women who received adjuvant systemic treatment had
a lower risk of developing a second breast cancer later
in life [27].
Some studies reported increased familial risks
among women with bilateral breast cancer [4, 28].
Carmichael et al. [3] reported a significantly higher
frequency of breast cancer family history among wo-
men with metachronous bilateral breast cancer, but not
among women with synchronous bilateral cancer . In-
tra et al. [25] did not observe an increased familial risks
among women with synchronous bilateral disease. Our
study includes data on family history of cancer sys-
tematically collected since 1990, for over 3,300 breast
cancer patients [29]. Women with highly increased
familial risk tend to have more synchronous and
metachronous bilateral breast cancer, but not signifi-
cantly so. Nevertheless, the number of patients with
unknown family history is rather important and we can
therefore not draw any clear conclusions.
Bilateral breast cancer is not considered a major
phenotype in carriers of BRCA1 or BRCA2 germ-line
mutations [12, 30] and, according to recent recom-
mendations, bilateral breast cancer patients who have
no first- or second-degree relative with breast or
ovarian cancer are not candidates for BRCA1/2 eval-
uation [31, 32].
Our study also suggests that patients with oestrogen
receptor negative tumours are at increased risk of
developing contralateral breast cancer later in life
compared with patients with oestrogen receptor posi-
tive tumours. This is probably due to the fact that the
majority of patients with oestrogen receptor positive
tumours received hormone therapy, which is known to
reduce the risk of contralateral breast cancer. We
realize that our study includes a quite large number of
patients with missing information on hormone receptor
status. However, subgroup analysis, including only
patients diagnosed after 1995 (year when the Geneva
cancer registry started recording hormone receptor
status), showed similar results.
Table 4 lists previous studies that compared survival
between women with bilateral and those with unilat-
Table 3 Unadjusted and adjusted effect of bilaterality on breast cancer specific survival
Unadjusted hazard ratios Adjusted hazard ratiosa
Unilateral breast cancer 1b 1b
Synchronous bilateral breast cancer 1.4 (1.1–1.8) 1.1 (0.9–1.5)
Metachronous bilateral breast cancerc 1.0 (0.8–1.3) 0.8 (0.5–1.4)
a Adjusted for age, social class, period of diagnosis, stage, grade, oestrogen receptor status, histology and treatment
b Reference
c For the calculation of breast cancer mortality risks after metachronous bilateral disease, the date of diagnosis of the second tumour
was taken as starting point
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eral breast cancer. Some studies found no significant
difference in survival rates between women with
unilateral and women with synchronous bilateral
breast cancer [3, 17, 19, 34], whereas other studies show
significantly impaired survival rates for patients with
synchronous disease [15, 18, 33]. For metachronous
bilateral breast cancer, mortality risks were inconsis-
tent between studies: some reported impaired survival
after metachronous breast cancer [13, 33, 34], whereas
others observed no difference in mortality risk [3, 19,
35]. Some authors did not differentiate between syn-
chronous and metachronous bilateral breast cancer.
They reported either similar mortality risks between
unilateral and bilateral breast cancer patients [4, 14, 21]
or impaired survival of women with bilateral disease [5,
20]. There are several explanations for the disagree-
ment between studies. Bilateral breast cancer is a
relatively rare event, often resulting in underpowered
studies. In addition, several studies included patients
with in situ cancer, which may have underestimated the
effect of bilaterality on survival, as in situ breast cancer
is associated with excellent prognosis. Finally, many
studies did not adjust the mortality risks for important
prognostic factors, such as age, stage at diagnosis, and
type of treatment.
In this population-based study, we included all
breast cancer patient cases occurring in a well-defined
population and we accounted for most established
prognostic factors, including treatment. We found
similar breast cancer mortality risks for women with
metachronous bilateral breast cancer, synchronous
bilateral breast cancer and unilateral breast cancer.
We calculated mortality risks of patients with
metachronous breast cancer taking the date of diag-
nosis of the second tumour as reference date. Thus, we
avoided a healthy patient bias, i.e. only healthy,
younger patients with good prognostic tumours live
long enough to develop a second breast cancer. As a
result, we could not draw any conclusions concerning
the impact of second metachronous breast cancer
occurrence on survival after breast cancer. However,
we can conclude that for women diagnosed with breast
cancer, the fact of having had breast cancer before
does not seem to impair their outcome.
In conclusion, bilaterality of breast cancer was not
associated with decreased survival, giving reassuring
evidence to both women and clinicians that the pres-
ence of a second cancer per se is not a sign of more
severe disease.
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